These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30715819)

  • 21. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
    Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
    Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
    Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
    Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
    Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
    Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
    Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
    Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
    Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.
    Van Veggel M; Westerman E; Hamberg P
    Clin Pharmacokinet; 2018 Jan; 57(1):21-29. PubMed ID: 28667459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.
    Redic KA; Hough SM; Price EM
    Onco Targets Ther; 2016; 9():2783-93. PubMed ID: 27274274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat.
    Chari A; Bhor M; Eldjerou L; Gilligan AM; Urniasz A; Globe D; Stetsovsky D; Varker H; Davis B; Bonafede M; Talcott J
    Future Oncol; 2018 Sep; 14(21):2149-2160. PubMed ID: 29846095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panobinostat: first global approval.
    Garnock-Jones KP
    Drugs; 2015 Apr; 75(6):695-704. PubMed ID: 25837990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
    Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.
    Richardson PG; Schlossman RL; Roy AN; Panneerselvam A; Acharyya S; Sopala M; Lonial S
    Br J Haematol; 2018 Jun; 181(5):628-636. PubMed ID: 29774521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
    Mangiacavalli S; Pochintesta L; Ravelli E; Baldini L; Ferretti VV; La Targia ML; Farina L; Cocito F; Cairoli R; Montefusco V; Corso A
    Leuk Lymphoma; 2015 Jun; 56(6):1901-2. PubMed ID: 25347423
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
    Berdeja JG; Hart LL; Mace JR; Arrowsmith ER; Essell JH; Owera RS; Hainsworth JD; Flinn IW
    Haematologica; 2015 May; 100(5):670-6. PubMed ID: 25710456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
    Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
    Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
    San-Miguel JF; Hungria VTM; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Na Nakorn T; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Salwender H; Sopala M; Redhu S; Paul S; Corrado C; Richardson PG
    Br J Haematol; 2017 Oct; 179(1):66-74. PubMed ID: 28653400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
    Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
    Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
    JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.